Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Giorgio Durante
Observed names:
Durante, Giorgio,
Durante, Giorgio <1993>,
G. Durante,
GIORGIO DURANTE
Institutions:
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
University of Bologna
Observed institutions:
Università Campus Bio-Medico,
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
Istituto Ortopedico Rizzoli,
University of Bologna
ORCID:
0000-0002-6396-1437
Observed ORCID:
0000-0002-6396-1437
OpenAlex ID:
A5006943411
Circulating microRNA biomarkers in melanoma and non-melanoma skin cancer
2022
·
Giorgio Durante
, Elisabetta Broseghini
, et al.
·
Expert Review of Molecular Diagnostics
·
48
Unraveling the role of microRNA/isomiR network in multiple primary melanoma pathogenesis
2021
·
Emi Dika
, Elisabetta Broseghini
, et al.
·
Cell Death and Disease
·
40
PDF
MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary
2021
·
Noemi Laprovitera
, Mattia Riefolo
, et al.
·
Molecular Oncology
·
36
PDF
Non-coding RNA dysregulation in skin cancers
2021
·
Giorgio Durante
, Francesca Comito
, et al.
·
Essays in Biochemistry
·
32
Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
2021
·
Marianna Carrabotta
, Maria Antonella Laginestra
, et al.
·
Cancer Research
·
31
Essential role of MED1 in the transcriptional regulation of ER-dependent oncogenic miRNAs in breast cancer
2018
·
Neha Nagpal
, Shivani Sharma
, et al.
·
Scientific Reports
·
22
PDF
Association of miR-146a-5p and miR-21-5p with Prognostic Features in Melanomas
2024
·
Maria Naddeo
, Elisabetta Broseghini
, et al.
·
Cancers
·
18
PDF
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary
2024
·
Andrea Cavazzoni
, Irene Salamon
, et al.
·
Molecular Therapy
·
5
Dysplastic nevi and melanoma: microRNAs tell a divergent story
2022
·
Giorgio Durante
, Giulia Veronesi
, et al.
·
Pathology - Research and Practice
·
5
Abstract 5160: Evaluation of circulating microRNAs as predictive and prognostic biomarkers for advanced melanoma patients
2024
·
Giorgio Durante
, Francesca Comito
, et al.
·
Cancer Research
·
3
Quantification of Tissue and Circulating MicroRNAs by Droplet Digital PCR
2025
·
Elisabetta Broseghini
, Beatrice Fontana
, et al.
·
Methods in molecular biology
·
2
Propolis for prevention of chemo-induced oral mucositis in breast cancer patients: A randomized controlled trial
2015
·
M. Piredda
, G. Facchinetti
, et al.
·
Annals of Oncology
·
2
Exploring the Role of TERT Promoter Mutations in Advanced Melanoma Treated With BRAF/MEK Inhibitors or Immune Checkpoint Inhibitors
2026
·
PAOLA VALERIA MARCHESE
, IRENE ZANNINI
, et al.
·
Anticancer Research
Circulating tumor cells as biomarkers in melanoma: techniques, challenges, and clinical applications
2026
·
Elisabetta Broseghini
, Giorgio Durante
, et al.
·
Frontiers in Cell and Developmental Biology
PDF
Cancer of unknown primary genomic profiling from cell-free DNA provides insights into CUP biology and vulnerabilities
2026
·
Roberta Roncarati
, Beatrice Fontana
, et al.
·
Frontiers in Medicine
PDF
Pre-treatment circulating microRNA signatures predict outcomes of anti-CD19 CAR T-cell therapy
2026
·
Maria Naddeo
, Roberta Roncarati
, et al.
·
Haematologica
PDF
Figure 3 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
2025
·
Marianna Carrabotta
, Maria Antonella Laginestra
, et al.
1461eP Exploring miRNA signatures as diagnostic biomarker in HNCUP
2025
·
D.M. Filippini
, E. Broseghini
, et al.
·
Annals of Oncology
Data from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
2023
·
Marianna Carrabotta
, Maria Antonella Laginestra
, et al.
Supplementary Data from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
2023
·
Marianna Carrabotta
, Maria Antonella Laginestra
, et al.
PDF
Supplementary Data from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
2023
·
Marianna Carrabotta
, Maria Antonella Laginestra
, et al.
Supplementary Data from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
2023
·
Marianna Carrabotta
, Maria Antonella Laginestra
, et al.
PDF
Supplementary Data from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
2023
·
Marianna Carrabotta
, Maria Antonella Laginestra
, et al.
Data from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
2023
·
Marianna Carrabotta
, Maria Antonella Laginestra
, et al.
Author response for "MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary"
2021
·
Noemi Laprovitera
, Mattia Riefolo
, et al.
·
Publons reviews and discussion
Show more works
View as search
Works count:
30
Citation count:
244
H-index:
7
I10-index:
7
Year
Topic
Type